Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL · Alpha
██.█% Sign up free to reveal

Amneal Pharmaceuticals, Inc. (AMRX) AI Forecast

Our AI analyzed Amneal Pharmaceuticals, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$AMRX Neutral Signal Full forecast available

Amneal Pharmaceuticals, Inc. (AMRX) Stock Forecast Sept. 24, 2026


Amneal Pharmaceuticals, Inc. (AMRX) AI Stock Price Forecast & Investment Analysis

Amneal Pharmaceuticals, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Amneal Pharmaceuticals, Inc. (AMRX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Amneal Pharmaceuticals, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Amneal Pharmaceuticals, Inc. Investment Summary

When evaluating whether Amneal Pharmaceuticals, Inc. (AMRX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Amneal Pharmaceuticals, Inc. (AMRX) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $6 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Amneal Pharmaceuticals, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Amneal Pharmaceuticals, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Amneal Pharmaceuticals, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Amneal Pharmaceuticals, Inc.

Sign Up Free
Corporate Identity

Amneal Pharmaceuticals, Inc. (Stock Symbol: AMRX) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Amneal Pharmaceuticals, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Amneal Pharmaceuticals, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Amneal Pharmaceuticals, Inc....

Unlock Full Company Profile

Get complete details about Amneal Pharmaceuticals, Inc.

Sign Up Free
Revenue & Growth Analysis

Amneal Pharmaceuticals, Inc. generates annual revenues of $3 billion , indicating a well-established business with proven market demand.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Amneal Pharmaceuticals, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Amneal Pharmaceuticals, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Amneal Pharmaceuticals, Inc....

Unlock Financial Analysis

Get complete financial metrics for Amneal Pharmaceuticals, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Amneal Pharmaceuticals, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Amneal Pharmaceuticals, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Amneal Pharmaceuticals, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company shows positive operational efficiency through free cash flow generation of $128 million annually , with year-over-year cash flow growth of -42.8%. Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.

Margin & Pricing Power Analysis

The company maintains a 39.3% gross margin reflecting moderate pricing power typical of many manufacturing, retail, or service businesses. While not exceptionally high, these margins provide adequate room for operating expenses and profit generation. Competitive pressures or cost increases could impact profitability if margins compress.

Financial Strength & Leverage

Current ratio of 2.20 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Amneal Pharmaceuticals, Inc. (AMRX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Amneal Pharmaceuticals, Inc. stock analysis.

Deep dive into Amneal Pharmaceuticals, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Amneal Pharmaceuticals, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Amneal Pharmaceuticals, Inc.:

Market Cap $6.32B
EPS $0.33
Revenue/Share $9.76
FCF/Share $0.40
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Amneal Pharmaceuticals, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Amneal Pharmaceuticals, Inc.:

ROIC -51.4%
Gross Margin 39.3%
Tax Rate -7.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Amneal Pharmaceuticals, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Amneal Pharmaceuticals, Inc.: A current ratio of 2.20 indicates strong liquidity.

Current Ratio 2.20x
Quick Ratio 1.44x
Interest Coverage 3.7x
Working Capital $1.06B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Amneal Pharmaceuticals, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Amneal Pharmaceuticals, Inc.: Free cash flow of $128M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $201M
Free Cash Flow $128M
Capital Spending -$73M
OCF Growth YoY -42.8%
FCF Growth YoY -54.8%
FCF/Sales 4.1%
CapEx/Sales 2.3%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Amneal Pharmaceuticals, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Amneal Pharmaceuticals, Inc.:

Inventory Turnover 2.8x
Fixed Assets Turnover 6.8x
Days Inventory 131 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Amneal Pharmaceuticals, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Amneal Pharmaceuticals, Inc.: With annual revenue of $3117M, Amneal Pharmaceuticals, Inc. operates at significant scale.

Income Statement
Total Revenue $3.12B
Operating Income $453M
R&D Expense $176M
SG&A Expense $572M
Cost of Goods Sold $1.89B
Balance Sheet Highlights (USD millions)
Total Current Assets $1.95B
Cash & Short-term Investments $128M
Inventory $678M
Total Liabilities $0.00M
Dividend & Shareholder Information
Shares Outstanding 319M

Latest Amneal Pharmaceuticals, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Amneal Pharmaceuticals, Inc. (AMRX) stock price and investment outlook.

📰 Loading...

Where AMRX sits on the market map

Explore the map →

Amneal Pharmaceuticals, Inc. Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Amneal Pharmaceuticals, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
AMRX ██% $6.32B x x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Amneal Pharmaceuticals, Inc. Stock Forecast

How accurate are Amneal Pharmaceuticals, Inc. stock predictions?

A per-ticker accuracy statistic for AMRX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Amneal Pharmaceuticals, Inc. stock price forecasts?

Our analysis considers Amneal Pharmaceuticals, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Amneal Pharmaceuticals, Inc. a good investment in 2026?

Based on our AI analysis, Amneal Pharmaceuticals, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Amneal Pharmaceuticals, Inc. forecasts updated?

Amneal Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Amneal Pharmaceuticals, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...